PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021652 001	ABACAVIR SULFATE;EPZICOM	5034394	DEC 18, 2011	DS DP		
			5089500	JUN 26, 2009	U257		
			6294540	MAY 14, 2018	DS DP U257		
			5047407	NOV 17, 2009	DS DP U257		
			5905082	MAY 18, 2016	DS DP		
			6417191	MAR 28, 2016	DP U257		
			6180639	JAN 30, 2018	DP U257		
	020977 001	ABACAVIR SULFATE;ZIAGEN				D-40	AUG 02, 2007
	020978 001	ABACAVIR SULFATE;ZIAGEN				D-40	AUG 02, 2007
	021320 001	ABARELIX;PLENAXIS	5968895	DEC 11, 2016	DP		
			6180608	DEC 11, 2016	DP U549		
			6423686	JUN 07, 2015	DS		
			6455499	JUN 07, 2015	U549		
			5843901	DEC 01, 2015	DS DP		
			6699833	DEC 11, 2016	DP		
	021431 001	ACAMPROSATE CALCIUM;CAMPRAL				NCE	JUL 29, 2009
	021539 001	ACETYLCYSTEINE;ACETADOTE				ODE	JAN 23, 2011
	021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6451340	JUL 23, 2018	DS DP U470		
			5663159	SEP 02, 2014	DS DP U470		
			6635278	DEC 15, 2018	DS DP		
	020899 001	ALBUMIN HUMAN;OPTISON	6723303	APR 20, 2021	DP		
	020949 001	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558		
	020949 002	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558		
>ADD>	021457 001	ALBUTEROL SULFATE;ALBUTEROL SULFATE				NP	OCT 29, 2007
	020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6315173	DEC 23, 2017	DP		
			6510969	DEC 23, 2017	DP		
			6131566	APR 14, 2015	DP U589		
			6532955	APR 14, 2015	DP U590		
	020560 005	ALENDRONATE SODIUM;FOSAMAX				D-87	APR 16, 2007
	021575 001	ALENDRONATE SODIUM;FOSAMAX				D-87	APR 16, 2007
	020886 001	ALITRETINOIN;PANRETIN	5932622	AUG 03, 2016	U562		
>ADD>	020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	6710066	JUL 28, 2009	U289		
	021727 001	AMLEXANOX;AMLEXANOX				NDF	SEP 29, 2007
	021540 001	AMLODIPINE BESYLATE;CADUET	5273995	DEC 28, 2010	DS DP U162	NC	JAN 30, 2007
			5273995*PED	JUN 28, 2011			
			6455574	AUG 11, 2018	U552		
			5969156	JUL 08, 2016	DS		
			5969156*PED	JAN 08, 2017			
			5686104	NOV 11, 2014	DP U213		
			5686104*PED	MAY 11, 2015			
			6126971	JAN 19, 2013	DP		
			6126971*PED	JUL 19, 2013			
			4681893	SEP 24, 2009	DS DP U161		
			4681893*PED	MAR 24, 2010			
			4879303	MAR 25, 2007	DS DP		
			4879303*PED	SEP 25, 2007			
			4572909	JUL 31, 2006	DS DP U3		
			4572909*PED	JAN 31, 2007			
	021540 002	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
			4681893*PED	MAR 24, 2010			
			4879303	MAR 25, 2007	DS DP		
			4879303*PED	SEP 25, 2007			
			4572909	JUL 31, 2006	DS DP U3		
			4572909*PED	JAN 31, 2007			
			5273995	DEC 28, 2010	DS DP U162		
			5273995*PED	JUN 28, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 003	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 004	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 005	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021540 006	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 007	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 008	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 009	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
			5686104	NOV 11, 2014	DP U213		
			5686104*PED	MAY 11, 2015			
			6126971	JAN 19, 2013	DP		
			6126971*PED	JUL 19, 2013			
	021540 010	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
			4681893*PED	MAR 24, 2010			
			4879303	MAR 25, 2007	DS DP		
			4879303*PED	SEP 25, 2007			
			4572909	JUL 31, 2006	DS DP U3		
			4572909*PED	JAN 31, 2007			
			5273995	DEC 28, 2010	DS DP U162		
			5273995*PED	JUN 28, 2011			
			6455574	AUG 11, 2018	U552		
			5969156	JUL 08, 2016	DS		
			5969156*PED	JAN 08, 2017			
			5686104	NOV 11, 2014	DP U213		
			5686104*PED	MAY 11, 2015			
			6126971	JAN 19, 2013	DP		
			6126971*PED	JUL 19, 2013			
	021540 011	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
			4681893*PED	MAR 24, 2010			
			4879303	MAR 25, 2007	DS DP		
			4879303*PED	SEP 25, 2007			
			4572909	JUL 31, 2006	DS DP U3		
			4572909*PED	JAN 31, 2007			
			5273995	DEC 28, 2010	DS DP U162		
			5273995*PED	JUN 28, 2011			
			6455574	AUG 11, 2018	U552		
			5969156	JUL 08, 2016	DS		
			5969156*PED	JAN 08, 2017			
			5686104	NOV 11, 2014	DP U213		
			5686104*PED	MAY 11, 2015			
			6126971	JAN 19, 2013	DP		
			6126971*PED	JUL 19, 2013			
>ADD>	021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
>ADD>			6605300*PED	APR 21, 2019		PED	APR 11, 2005
>ADD>	021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
>ADD>			6605300*PED	APR 21, 2019		PED	APR 11, 2005
>ADD>	021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
>ADD>			6605300*PED	APR 21, 2019		PED	APR 11, 2005
>ADD>	021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
>ADD>			6605300*PED	APR 21, 2019		PED	APR 11, 2005
>ADD>	021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
>ADD>			6605300*PED	APR 21, 2019		PED	APR 11, 2005
>ADD>	021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
>ADD>			6605300*PED	APR 21, 2019		PED	APR 11, 2005
>ADD>	011522 007	AMPHETAMINE ASPARTATE;ADDERALL 10	6384020*PED	JAN 06, 2021			
>ADD>	011522 012	AMPHETAMINE ASPARTATE;ADDERALL 12.5	6384020*PED	JAN 06, 2021			
>ADD>	011522 013	AMPHETAMINE ASPARTATE;ADDERALL 15	6384020*PED	JAN 06, 2021			
>ADD>	011522 008	AMPHETAMINE ASPARTATE;ADDERALL 20	6384020*PED	JAN 06, 2021			
>ADD>	011522 010	AMPHETAMINE ASPARTATE;ADDERALL 30	6384020*PED	JAN 06, 2021			
>ADD>	011522 009	AMPHETAMINE ASPARTATE;ADDERALL 5	6384020*PED	JAN 06, 2021			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	011522 011	AMPHETAMINE ASPARTATE;ADDERALL 7.5	6384020*PED	JAN 06, 2021			
	021007 001	AMPRENAVIR;AGENERASE	6730679	NOV 11, 2017	DP		
	021007 002	AMPRENAVIR;AGENERASE	6730679	NOV 11, 2017	DP		
	020333 001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
						PED	SEP 14, 2004
	020333 002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
						PED	SEP 14, 2004
	021264 001	APOMORPHINE HYDROCHLORIDE;APOKYN				NCE	APR 20, 2009
>ADD>						ODE	APR 20, 2011
	021264 002	APOMORPHINE HYDROCHLORIDE;APOKYN				NCE	APR 20, 2009
>ADD>						ODE	APR 20, 2011
	021436 001	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 002	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 003	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 004	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 005	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 006	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021248 001	ARSENIC TRIOXIDE;TRISENOX	6723351	NOV 10, 2018	U573		
	008809 006	ASCORBIC ACID;M.V.I.-12 (WITHOUT V				ODE	SEP 09, 2011
	021567 001	ATAZANAVIR SULFATE;REYATAZ				D-89	JUL 06, 2007
	021567 002	ATAZANAVIR SULFATE;REYATAZ				D-89	JUL 06, 2007
	021567 003	ATAZANAVIR SULFATE;REYATAZ				D-89	JUL 06, 2007
	020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
			5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
			5686104	NOV 11, 2014	DP U213		
			5969156	JUL 08, 2016	DS		
			6126971	JAN 19, 2013	DP		
	020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
			5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
			5686104	NOV 11, 2014	DP U213		
			5969156	JUL 08, 2016	DS		
			6126971	JAN 19, 2013	DP		
	020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
			5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
			5686104	NOV 11, 2014	DP U213		
			5969156	JUL 08, 2016	DS		
			6126971	JAN 19, 2013	DP		
	020702 004	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
			5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
			5686104	NOV 11, 2014	DP U213		
			5969156	JUL 08, 2016	DS		
			6126971	JAN 19, 2013	DP		
>ADD>	050794 001	AZACITIDINE;VIDAZA				ODE	MAY 19, 2011
	020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2010	U207		
			5164194*PED	MAY 01, 2011			
	020610 001	BALSALAZIDE DISODIUM;COLAZAL	4412992	JUL 08, 2006			
	019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	021551 001	BISACODYL;HALFLYTELY				NP	MAY 10, 2007
	021602 001	BORTEZOMIB;VELCADE	6713446	JAN 25, 2022	DP		
			6747150	OCT 28, 2014	DP		
	020746 001	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
	020746 002	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
>ADD>	020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5989588*PED	MAR 30, 2016	U349		
	019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
			4657927*PED	OCT 14, 2004			
	019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
			4657927*PED	OCT 14, 2004			
	019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
			4657927*PED	OCT 14, 2004			
	020452 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020452 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020452 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020452 004	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020637 001	CARMUSTINE;GLIADEL				ODE	FEB 25, 2010
>ADD>	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017	DP	I-438	SEP 29, 2007
>ADD>			5378804	MAR 16, 2013	DS		
>ADD>			5514650	MAR 16, 2013	DP U607		
>ADD>			5792746	MAR 16, 2013	DS DP U607		
>ADD>			6136783	MAR 28, 2017	U607		
>ADD>	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017	DP	I-438	SEP 29, 2007
>ADD>			5378804	MAR 16, 2013	DS		
>ADD>			5514650	MAR 16, 2013	DP U607		
>ADD>			5792746	MAR 16, 2013	DS DP U607		
>ADD>			6136783	MAR 28, 2017	U607		
	021621 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007	DS DP U565		
			4525358*PED	DEC 25, 2007			
			6455533	JUL 02, 2018	DP		
	021621 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007	DS DP U565		
			4525358*PED	DEC 25, 2007			
			6455533	JUL 02, 2018	DP		
	020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	5340821	JUL 07, 2013	U309		
	021587 001	CHLORPHENIRAMINE MALEATE;CHILDREN’S ADVIL ALL				NP	FEB 24, 2007
	021149 002	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015	DS		
			6706681	MAR 16, 2021	DP		
	021688 001	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
			6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
			6313146	DEC 14, 2016	DS DP		
			6011068	DEC 14, 2016	DS DP		
	021688 002	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016		ODE	MAR 08, 2011
			6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
			6313146	DEC 14, 2016	DS DP		
			6011068	DEC 14, 2016	DS DP		
	021688 003	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
			6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
			6313146	DEC 14, 2016	DS DP		
			6011068	DEC 14, 2016	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	5965549	JUN 06, 2015	DP		
075593 002	CIPROFLOXACIN HYDROCHLORIDE;CIPROFLOXACIN				PC	FEB 05, 2005
019847 001	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
020780 001	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
020780 002	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLO	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
		4670444*PED	JUN 09, 2004			
		4705789*PED	MAY 10, 2005			
		4808583*PED	AUG 28, 2006			
		4957922*PED	MAR 18, 2008			
021473 002	CIPROFLOXACIN;CIPRO XR	4670444	DEC 09, 2003	DS DP U555	NS	AUG 28, 2006
		4670444*PED	JUN 09, 2004		PED	FEB 28, 2007
021644 001	CLOBETASOL PROPIONATE;CLOBEX				NDF	FEB 05, 2007
021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2005	U427		
		4659716*PED	OCT 21, 2005	U427		
021312 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2005	U427		
		4659716*PED	OCT 21, 2005	U427		
021038 001	DEXMEDETOMIDINE;PRECEDEX	6716867	MAR 31, 2019	U572		
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6528530	DEC 04, 2015	DS DP		
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6528530	DEC 04, 2015	DS DP		
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6528530	DEC 04, 2015	DS DP		
021392 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
021392 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
021392 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
021392 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
021392 005	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
021392 006	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6528090	DEC 18, 2018	DP		
		6713086	DEC 18, 2018	DP U579		
		5212326	JAN 29, 2008	DS DP		
		6528091	DEC 18, 2018	U106		
021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	6528090	DEC 18, 2018	DP		
		6713086	DEC 18, 2018	DP U579		
		5212326	JAN 29, 2008	DS DP		
020449 001	DOCETAXEL;TAXOTERE				I-429	MAY 19, 2007
					I-436	AUG 18, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020931 001	DOFETILIDE;TIKOSYN	4959366	SEP 25, 2007			
	020931 002	DOFETILIDE;TIKOSYN	4959366	SEP 25, 2007			
	020931 003	DOFETILIDE;TIKOSYN	4959366	SEP 25, 2007			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	6316443	APR 17, 2011	DP U561		
	020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	DS DP U103		
			4619939	OCT 28, 2003	DP U104		
	020862 001	DOXERCALCIFEROL;HECTOROL				I-424	APR 23, 2007
	020862 002	DOXERCALCIFEROL;HECTOROL	5869473	AUG 02, 2008	U278	I-424	APR 23, 2007
	018651 001	DRONABINOL;MARINOL	6703418	FEB 26, 2011	U563		
	018651 002	DRONABINOL;MARINOL	6703418	FEB 26, 2011	U563		
	018651 003	DRONABINOL;MARINOL	6703418	FEB 26, 2011	U563		
	021098 001	DROSPIRENONE;YASMIN	6787531	AUG 31, 2020	DP		
	021427 001	DULOXETINE HYDROCHLORIDE;CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
			5508276	JUL 18, 2014	DP		
	021427 002	DULOXETINE HYDROCHLORIDE;CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
			5508276	JUL 18, 2014	DP		
	021427 004	DULOXETINE HYDROCHLORIDE;CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
			5508276	JUL 18, 2014	DP		
	021733 001	DULOXETINE HYDROCHLORIDE;CYMBALTA				NCE	AUG 03, 2009
						NDF	SEP 03, 2007
	021733 002	DULOXETINE HYDROCHLORIDE;CYMBALTA				NCE	AUG 03, 2009
						NDF	SEP 03, 2007
	021733 004	DULOXETINE HYDROCHLORIDE;CYMBALTA				NCE	AUG 03, 2009
						NDF	SEP 03, 2007
	021500 001	EMTRICITABINE;EMTRIVA	6703396	MAR 09, 2021	DS DP		
>ADD>	021486 001	EPINEPHRINE;LIDOCAINE HCL AND EP				NP	OCT 26, 2007
	021504 001	EPINEPHRINE;LIDOSITE TOPICAL SYS	5246418	SEP 30, 2013	DS DP	NP	MAY 04, 2007
			5873850	SEP 30, 2013	DS DP		
			6377847	SEP 30, 2013	DS DP		
			6385488	SEP 30, 2013	DS DP		
			6629968	JUN 30, 2020	DS DP		
			6635045	JUN 29, 2021	DS DP		
	021437 001	EPLERENONE;INSPRA	6747020	NOV 05, 2019	U587		
	021437 002	EPLERENONE;INSPRA	6747020	NOV 05, 2019	U587		
	021437 003	EPLERENONE;INSPRA	6747020	NOV 05, 2019	U587		
	021633 001	ESTRADIOL ACETATE;FEMTRACE				NDF	AUG 20, 2007
	021633 002	ESTRADIOL ACETATE;FEMTRACE				NDF	AUG 20, 2007
	021633 003	ESTRADIOL ACETATE;FEMTRACE				NDF	AUG 20, 2007
	021371 001	ESTRADIOL HEMIHYDRATE;ESTRASORB	5629021	JAN 31, 2015	DP	NDF	OCT 09, 2006
	021166 001	ESTRADIOL;ESTROGEL				NDF	FEB 09, 2007
	021674 001	ESTRADIOL;MENOSTAR	5891868	NOV 21, 2017	DP U594	NP	JUN 08, 2007
			6692763	NOV 21, 2017	DP U594		
			5223261	JUN 29, 2010	DP U594		
	021040 001	ESTRADIOL;PREFEST	6747019	MAR 20, 2020	U311		
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				D-85	FEB 05, 2007
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				D-85	FEB 05, 2007
	020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				D-85	FEB 05, 2007
	020992 006	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NS	FEB 05, 2007
						D-85	FEB 05, 2007
	021443 003	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA				NP	MAY 10, 2007
	021443 004	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA				NP	MAY 10, 2007
	021490 001	ETHINYL ESTRADIOL;OVCON-35	6667050	JUN 12, 2021	DP U1		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021687 001	EZETIMIBE;VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		
021687 002	EZETIMIBE;VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		
021687 003	EZETIMIBE;VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		
021687 004	EZETIMIBE;VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		
020363 001	FAMCICLOVIR;FAMVIR	5840763	SEP 01, 2015	U96		
		5866581	OCT 04, 2014	U96		
		5916893	SEP 01, 2015	U96		
		6124304	OCT 04, 2014	U96		
020363 002	FAMCICLOVIR;FAMVIR	5840763	SEP 01, 2015	U96		
		5866581	OCT 04, 2014	U96		
		5916893	SEP 01, 2015	U96		
		6124304	OCT 04, 2014	U96		
020363 003	FAMCICLOVIR;FAMVIR	5840763	SEP 01, 2015	U96		
		5866581	OCT 04, 2014	U96		
		5916893	SEP 01, 2015	U96		
		6124304	OCT 04, 2014	U96		
019922 001	FENOLDOPAM MESYLATE;CORLOPAM				I-422	APR 01, 2007
020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	DS DP U262		
		5886184	NOV 19, 2012	DS		
		6046183	MAR 20, 2011	DP U577		
019949 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019949 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019949 003	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019949 004	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020090 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020090 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 003	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 005	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 001	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 002	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 004	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020985 001	FLUOROURACIL;CARAC	6670335	JUN 02, 2021	DP U68		
021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017	U396		
		5985322	MAY 29, 2017	U397		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50				M-33	APR 21, 2007
021433 001	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 002	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 003	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021211 001	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
		5767251	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U568		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
021211 002	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
		4589402	JUL 26, 2004	U568		
		5767251	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS		
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS		
020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS		
020378 004	FOLLITROPIN ALFA/BETA;GONAL-F	5767067	JUN 16, 2015	DS	ODE	MAY 24, 2007
		5767251	JUN 16, 2015	DS		
020378 005	FOLLITROPIN ALFA/BETA;GONAL-F	5767067	JUN 16, 2015	DS	ODE	MAY 24, 2007
		5767251	JUN 16, 2015	DS		
021765 001	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	NP	MAR 25, 2007
021765 002	FOLLITROPIN ALFA/BETA;GONAL-F	5767067	JUN 16, 2015	DS	NP	MAR 25, 2007
		5767251	JUN 16, 2015	DS		
021765 003	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	NP	MAR 25, 2007
021684 001	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS		
		5767251	JUN 16, 2015	DS		
021684 002	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS		
		5767251	JUN 16, 2015	DS		
021684 003	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS		
		5767251	JUN 16, 2015	DS		
021345 001	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
					I-427	MAY 31, 2007
021345 002	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
					NCE	DEC 07, 2006
					I-397	JUN 17, 2006
					NS	MAY 31, 2007
					I-427	MAY 31, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021345 003	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
						NCE	DEC 07, 2006
						I-397	JUN 17, 2006
						NS	MAY 31, 2007
						I-427	MAY 31, 2007
	021345 004	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
						NCE	DEC 07, 2006
						I-397	JUN 17, 2006
						NS	MAY 31, 2007
						I-427	MAY 31, 2007
>ADD>	021344 001	FULVESTRANT;FASLODEX	4659516	OCT 01, 2005			
			6774122	JAN 09, 2021	U596		
>ADD>	075350 001	GABAPENTIN;GABAPENTIN				PC	APR 06, 2005
>ADD>	075350 002	GABAPENTIN;GABAPENTIN				PC	APR 06, 2005
>ADD>	075350 003	GABAPENTIN;GABAPENTIN				PC	APR 06, 2005
	076017 001	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
	076017 002	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
	076017 003	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
	021061 001	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021061 002	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 001	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 002	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 003	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 004	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021678 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007	DS	NCE	DEC 17, 2004
			5880283	DEC 05, 2015	DS	I-329	OCT 17, 2005
			6589955	MAY 09, 2022	DS U603		
	021493 001	GATIFLOXACIN;ZYMAR	4980470	DEC 25, 2007			
			6333045	AUG 20, 2019	DP		
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2004
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2007
>ADD>	021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6803376	SEP 21, 2019	DS DP U608		
>ADD>			6803376	SEP 21, 2019	U609		
			6723734	MAR 20, 2018	DS DP		
	021667 001	GLUTAMINE;NUTRESTORE				NCE	JUN 10, 2009
>ADD>						ODE	JUN 10, 2011
>ADD>	021178 001	GLYBURIDE;GLUCOVANCE				M-37	MAR 15, 2007
>ADD>						PED	SEP 15, 2007
>ADD>	021178 002	GLYBURIDE;GLUCOVANCE				M-37	MAR 15, 2007
>ADD>						PED	SEP 15, 2007
>ADD>	021178 003	GLYBURIDE;GLUCOVANCE				M-37	MAR 15, 2007
>ADD>						PED	SEP 15, 2007
	076345 001	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	076345 002	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	076345 003	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
>ADD>	021732 001	HISTRELIN ACETATE;VANTAS				NDF	OCT 12, 2007
>ADD>	021665 001	HYALURONIDASE;AMPHADASE				NCE	OCT 26, 2009
>ADD>	021640 001	HYALURONIDASE;VITRASE				NCE	MAY 05, 2009
	020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
			5994348	JUN 07, 2015			
			5270317*PED	MAR 30, 2012			
			5994348*PED	DEC 07, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
			5994348	JUN 07, 2015			
			5270317*PED	MAR 30, 2012			
			5994348*PED	DEC 07, 2015			
	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
			5994348	JUN 07, 2015			
			5270317*PED	MAR 30, 2012			
			5994348*PED	DEC 07, 2015			
>ADD>	076374 001	HYDROCHLOROTHIAZIDE;QUINARETIC				PC	NOV 08, 2004
>ADD>	076374 002	HYDROCHLOROTHIAZIDE;QUINARETIC				PC	NOV 08, 2004
>ADD>	076374 003	HYDROCHLOROTHIAZIDE;QUINARETIC				PC	NOV 08, 2004
	076604 001	HYDROCODONE BITARTRATE;HYDROCODONE BITARTRA				PC	OCT 11, 2004
>ADD>	076642 002	HYDROCODONE BITARTRATE;HYDROCODONE BITARTRA				PC	DEC 05, 2004
	021044 001	HYDROMORPHONE HYDROCHLORIDE;PALLADONE				NDF	SEP 24, 2007
	021044 002	HYDROMORPHONE HYDROCHLORIDE;PALLADONE				NDF	SEP 24, 2007
	021044 003	HYDROMORPHONE HYDROCHLORIDE;PALLADONE				NDF	SEP 24, 2007
	021044 004	HYDROMORPHONE HYDROCHLORIDE;PALLADONE				NDF	SEP 24, 2007
	021604 001	IBUPROFEN;CHILDREN'S ELIXSURE				NP	JAN 07, 2007
	076478 001	IBUPROFEN;IBUPROFEN AND PSEUDO				PC	JUL 29, 2004
	020723 001	IMIQUIMOD;ALDARA				I-420	MAR 02, 2007
						I-433	JUL 14, 2007
	020685 001	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	020685 003	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	020685 005	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	020685 006	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	021629 001	INSULIN GLULISINE RECOMBINANT;APIDRA	6221633	JUN 18, 2018	DS DP U471	NCE	APR 16, 2009
	020563 001	INSULIN LISPRO RECOMBINANT;HUMALOG				D-86	JUN 02, 2007
	020563 002	INSULIN LISPRO RECOMBINANT;HUMALOG PEN				D-86	JUN 02, 2007
	021425 003	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	DS DP U113		
	020757 001	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
			6342247	JUN 07, 2015		PED	MAR 17, 2006
			5270317*PED	MAR 30, 2012			
			6342247*PED	DEC 07, 2015			
	020757 002	IRBESARTAN;AVAPRO	5270317*PED	MAR 30, 2012		I-373	SEP 17, 2005
			6342247*PED	DEC 07, 2015		PED	MAR 17, 2006
	020757 003	IRBESARTAN;AVAPRO	5270317*PED	MAR 30, 2012		I-373	SEP 17, 2005
						PED	MAR 17, 2006
>ADD>	020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	6794370	MAY 01, 2020	U606	M-34	JUN 24, 2007
>ADD>			6794370*PED	NOV 01, 2020		PED	DEC 24, 2007
			4604463	AUG 20, 2007			
			6403569	APR 28, 2020	U449		
			4604463*PED	FEB 20, 2008			
			6403569*PED	OCT 28, 2020			
	021066 001	KETOTIFEN FUMARATE;ZADITOR	6777429	JAN 13, 2019	DP		
			6774137	JAN 13, 2019	U599		
			6776982	JAN 13, 2019	DP		
	021281 001	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
	021281 002	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
	021428 001	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
	021428 002	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
	021566 001	LANSOPRAZOLE;PREVACID IV				NDF	MAY 27, 2007
>ADD>	021468 001	LANTHANUM CARBONATE;FOSRENOL				NCE	OCT 26, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021468 002	LANTHANUM CARBONATE;FOSRENOL				NCE	OCT 26, 2009
	020905 001	LEFLUNOMIDE;ARAVA				M-32	MAR 05, 2007
						PED	SEP 05, 2007
	020905 002	LEFLUNOMIDE;ARAVA				M-32	MAR 05, 2007
						PED	SEP 05, 2007
	020905 003	LEFLUNOMIDE;ARAVA				M-32	MAR 05, 2007
						PED	SEP 05, 2007
	020837 004	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6083993	JAN 05, 2010	U332		
			6451289	MAR 21, 2021	DP		
			5362755	NOV 08, 2011	U332		
			5547994	AUG 20, 2013	U332		
			5760090	JAN 05, 2010	U332		
			5844002	JAN 05, 2010	U5		
	020182 001	LEVOCARNITINE;CARNITOR	6696493	JAN 18, 2021	U433		
	021571 001	LEVOFLOXACIN;IQUIX	5053407	DEC 20, 2010	DS DP U600	NP	MAR 01, 2007
	021225 001	LEVONORGESTREL;MIRENA	5785053	DEC 05, 2015	DP		
	021451 001	LIDOCAINE;ORAQIX	6031007	APR 01, 2017	DP U553		
	021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
			6559305	JAN 29, 2021	DS		
	021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
			6559305	JAN 29, 2021	DS		
	021131 001	LINEZOLID;ZYVOX	6559305	JAN 29, 2021	DS	I-431	JUN 23, 2007
	021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
			6559305	JAN 29, 2021	DS		
	021226 001	LOPINAVIR;KALETRA	6703403	JUN 26, 2016	U257		
	021251 001	LOPINAVIR;KALETRA	6703403	JUN 26, 2016	U257		
	075505 001	LORATADINE;LORATADINE				PC	AUG 20, 2004
	020386 001	LOSARTAN POTASSIUM;COZAAR				NPP	MAR 11, 2007
						PED	SEP 11, 2007
	020386 002	LOSARTAN POTASSIUM;COZAAR				NPP	MAR 11, 2007
						PED	SEP 11, 2007
	020386 003	LOSARTAN POTASSIUM;COZAAR				NPP	MAR 11, 2007
						PED	SEP 11, 2007
	020803 001	LOTEPREDNOL ETABONATE;ALREX	5747061	OCT 25, 2013	DP U576		
	020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	5747061	OCT 25, 2013	DP U575		
	021249 001	LOVASTATIN;ADVICOR	6676967	SEP 20, 2013	U548		
			6746691	SEP 20, 2013	U586		
	021249 002	LOVASTATIN;ADVICOR	6676967	SEP 20, 2013	U548		
			6746691	SEP 20, 2013	U586		
	021249 003	LOVASTATIN;ADVICOR	6676967	SEP 20, 2013	U548		
			6746691	SEP 20, 2013	U586		
>ADD>	021663 001	MENOTROPINS (FSH;LH);MENOPUR				NP	OCT 29, 2007
>ADD>	021322 001	LUTROPIN ALFA;LUVERIS				ODE	OCT 08, 2011
	020938 001	MELOXICAM;MOBIC				I-430	JUL 16, 2007
	020938 002	MELOXICAM;MOBIC				I-430	JUL 16, 2007
	021530 001	MELOXICAM;MOBIC	6184220	MAR 25, 2019	DP	I-430	JUL 16, 2007
						NCE	APR 13, 2005
	013217 001	METAXALONE;SKELAXIN	6683102	DEC 03, 2021	U189		
	013217 003	METAXALONE;SKELAXIN	6683102	DEC 03, 2021	U189		
	021574 001	METFORMIN HYDROCHLORIDE;FORTAMET	6790459	MAR 17, 2021	U604	NP	APR 27, 2007
			6495162	MAR 20, 2018	DP		
			6099859	MAR 20, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021574 002	METFORMIN HYDROCHLORIDE;FORTAMET	6790459	MAR 17, 2021	U604	NP	APR 27, 2007
		6495162	MAR 20, 2018	DP		
		6099859	MAR 20, 2018	DP		
076172 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC	DEC 14, 2004
076545 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC	MAY 29, 2004
021415 001	METHYL AMINOLEVULINATE HYDROCHLORIDE;METHYL AMINOLEVULINA				NE	JUL 27, 2007
021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP		
		6635284	DEC 04, 2015	DP U591		
021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP		
		6635284	DEC 04, 2015	DP U591		
021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP		
		6635284	DEC 04, 2015	DP U591		
021284 004	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP		
		6635284	DEC 04, 2015	DP U591		
021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI				RTO	JUN 29, 2004
					D-90	OCT 01, 2007
076307 001	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 14, 2004
076307 002	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 14, 2004
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	6723713	JAN 27, 2014	U574		
		6723713*PED	JUL 27, 2014			
021671 001	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
021671 002	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
021671 003	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	6716830	SEP 20, 2019	DP	NCE	DEC 10, 2004
		6716830*PED	MAR 29, 2020		PED	JUN 10, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020381 001	NIACIN;NIASPAN	6746691	SEP 20, 2013	U586		
020381 002	NIACIN;NIASPAN	6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 003	NIACIN;NIASPAN	6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 004	NIACIN;NIASPAN	6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 005	NIACIN;NIASPAN TITRATION ST	6746691	SEP 20, 2013	U586		
021497 001	NITAZOXANIDE;ALINIA				NDF	JUL 21, 2007
					NCE	NOV 22, 2007
					ODE	NOV 22, 2009
021498 001	NITAZOXANIDE;ALINIA				NPP	JUL 21, 2007
					ODE	NOV 22, 2009
076648 001	NITROFURANTOIN;NITROFURANTOIN (MONO				PC	SEP 19, 2004
021494 001	NIZATIDINE;AXID				NDF	MAY 25, 2007
020592 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2001	U547		
020592 002	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 003	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 004	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 006	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	DS DP U547		
021253 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U571	NDF	MAR 29, 2007
					NP	MAR 29, 2007
021086 001	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021086 002	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021086 003	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021086 004	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021636 001	OMEPRAZOLE;ZEGERID	5840737	JUL 16, 2016	U588		
		6645988	JUL 16, 2016	DS DP		
		6489346	JUL 16, 2016	DS DP U588		
		6699885	JUL 16, 2016	U588		
		6780882	JUL 16, 2016	DS DP		
>ADD> 020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5854270	NOV 20, 2015	DP U610		
021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
		5866601	FEB 02, 2016		PED	APR 27, 2005
		5952375	FEB 02, 2016			
		5763483*PED	JUN 27, 2017			
		5866601*PED	AUG 02, 2016			
		5952375*PED	AUG 02, 2016			
021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5866601	FEB 02, 2016		NCE	OCT 27, 2004
		5952375	FEB 02, 2016		PED	APR 27, 2005
		5763483	DEC 27, 2016	U376		
		5763483*PED	JUN 27, 2017			
		5866601*PED	AUG 02, 2016			
		5952375*PED	AUG 02, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021492 001	OXALIPLATIN;ELOXATIN				I-425	JAN 09, 2007
	021492 002	OXALIPLATIN;ELOXATIN				I-425	JAN 09, 2007
	013718 001	OXANDROLONE;OXANDRIN	5872147	DEC 05, 2017	U585		
			6670351	OCT 20, 2012	U585		
			6576659	DEC 05, 2017	U585		
			6090799	JUL 18, 2017	U585		
	013718 002	OXANDROLONE;OXANDRIN	5872147	DEC 05, 2017	U585		
			6670351	OCT 20, 2012	U585		
			6576659	DEC 05, 2017	U585		
			6090799	JUL 18, 2017	U585		
	021351 002	OXYBUTYNIN;OXYTROL	6743441	APR 26, 2020	DP U318		
	076168 001	OXYCODONE HYDROCHLORIDE;OXYCODONE HCL				PC	SEP 26, 2004
	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	6780881	NOV 17, 2021	DP		
	020819 001	PARICALCITOL;ZEMPLAR				M-31	MAR 31, 2007
						PED	OCT 01, 2007
	020819 002	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012	U314	M-31	MAR 31, 2007
			5246925*PED	OCT 17, 2012		PED	OCT 01, 2007
			5587497	DEC 24, 2013			
			5587497*PED	JUN 24, 2014			
			6136799	APR 08, 2018			
			6136799*PED	OCT 08, 2019			
			6361758	APR 08, 2018	DP		
			6361758*PED	OCT 08, 2018			
>ADD>	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR				D-91	JAN 27, 2007
>ADD>	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR				D-91	JAN 27, 2007
>ADD>	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR				D-91	JAN 27, 2007
	021462 001	PEMETREXED DISODIUM;ALIMTA	5217974	MAR 29, 2011	U551	NCE	FEB 04, 2009
			5344932	SEP 06, 2011	DS DP	ODE	FEB 04, 2011
	020629 001	PENCICLOVIR SODIUM;DENAVIR	5840763	SEP 01, 2015	U501		
			5866581	SEP 04, 2014	U501		
			5916893	SEP 01, 2015	U501		
			6124304	SEP 04, 2014	U501		
	021749 001	PENTETATE CALCIUM TRISODIUM;PENTETATE CALCIUM TR				NCE	AUG 11, 2009
>ADD>						ODE	AUG 11, 2011
	021751 001	PENTETATE ZINC TRISODIUM;PENTETATE ZINC TRISO				NCE	AUG 11, 2009
>ADD>						ODE	AUG 11, 2011
	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
	020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	6797719	MAR 10, 2017	DP		
	021698 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				NP	AUG 31, 2007
	020741 001	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020741 002	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020741 003	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020903 002	RIBAVIRIN;REBETOL	6177074	NOV 01, 2016	U454		
		6177074*PED	MAY 01, 2017	U454		
		6461605	NOV 01, 2016	U478		
		6461605*PED	MAY 01, 2017	U478		
		6472373	SEP 21, 2017	U479		
		6472373*PED	MAR 21, 2018	U479		
		6524570	NOV 01, 2016	U499		
		6524570*PED	MAY 01, 2017	U499		
076203 001	RIBAVIRIN;RIBASPHERE				PC	OCT 03, 2004
076192 001	RIBAVIRIN;RIBAVIRIN				PC	OCT 03, 2004
021361 001	RIFAXIMIN;XIFAXAN				NCE	MAY 25, 2009
020835 003	RISEDRONATE SODIUM;ACTONEL	6465443	AUG 14, 2018	DP		
		6432932	JUL 17, 2018	U595		
020659 001	RITONAVIR;NORVIR	6703403	JUN 26, 2016	U564		
020945 001	RITONAVIR;NORVIR	6703403	JUN 26, 2016	U564		
021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U602	M-27	AUG 06, 2006
		6239173	JUN 24, 2013	DS DP U602	PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
		5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
		6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007
		6239173*PED	DEC 24, 2013			
021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U602	M-27	AUG 06, 2006
		6239173	JUN 24, 2013	DS DP U602	PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
		5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
		6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007
		6239173*PED	DEC 24, 2013			
021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
		5474995	JUN 24, 2013	DS DP U602	I-353	APR 11, 2005
		5691374	MAY 18, 2015		M-27	AUG 06, 2006
		6063811	MAY 06, 2017	U602	PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
		5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
		6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007
		6239173*PED	DEC 24, 2013			
021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013		PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	FEB 06, 2007
		5691374*PED	NOV 18, 2015		PED	OCT 11, 2005
		6063811*PED	NOV 06, 2017			
		6239173*PED	DEC 24, 2013			
021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013		PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	FEB 06, 2007
		5691374*PED	NOV 18, 2015		PED	OCT 11, 2005
		6063811*PED	NOV 06, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
			6239173*PED	DEC 24, 2013			
	021256 001	SECRETIN SYNTHETIC HUMAN;CHIRHOSTIM				ODE	APR 04, 2009
						NCE	APR 09, 2009
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	6727283	OCT 11, 2019	DP U580		
	020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013			
	021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013			
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			4929629	MAY 29, 2007			
			5436272	JUL 25, 2012	U439		
			4746680*PED	DEC 11, 2007			
			4929629*PED	NOV 29, 2007			
			5436272*PED	JAN 25, 2013			
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			4929629	MAY 29, 2007			
			5436272	JUL 25, 2012	U439		
			4746680*PED	DEC 11, 2007			
			4929629*PED	NOV 29, 2007			
			5436272*PED	JAN 25, 2013			
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			4929629	MAY 29, 2007			
			5436272	JUL 25, 2012	U439		
			4746680*PED	DEC 11, 2007			
			4929629*PED	NOV 29, 2007			
			5436272*PED	JAN 25, 2013			
	021110 003	SIROLIMUS;RAPAMUNE				NCE	SEP 15, 2004
						I-386	APR 11, 2006
	020955 001	SODIUM FERRIC GLUCONATE COMPLEX;FERRLECIT				NPP	AUG 13, 2007
						PED	FEB 13, 2008
	021196 001	SODIUM OXYBATE;XYREM	6780889	DEC 22, 2019	DP		
	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	4968299	JUN 28, 2008	DP		
>ADD>	021148 001	SOMATROPIN RECOMBINANT;NORDITROPIN				I-439	NOV 01, 2007
>ADD>	021148 002	SOMATROPIN RECOMBINANT;NORDITROPIN				I-439	NOV 01, 2007
>ADD>	021148 003	SOMATROPIN RECOMBINANT;NORDITROPIN				I-439	NOV 01, 2007
>ADD>	021148 004	SOMATROPIN RECOMBINANT;NORDITROPIN NORDIFLE				I-439	NOV 01, 2007
>ADD>	021148 005	SOMATROPIN RECOMBINANT;NORDITROPIN NORDIFLE				I-439	NOV 01, 2007
>ADD>	021148 006	SOMATROPIN RECOMBINANT;NORDITROPIN NORDIFLE				I-439	NOV 01, 2007
	020168 001	SOMATROPIN RECOMBINANT;NUTROPIN	5096885	MAR 17, 2009	DP		
	020168 002	SOMATROPIN RECOMBINANT;NUTROPIN	5096885	MAR 17, 2009	DP		
	020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ	5763394	JUN 09, 2015	DP		
	020522 002	SOMATROPIN RECOMBINANT;NUTROPIN AQ PEN	5763394	JUN 09, 2015	DP		
>ADD>	019764 001	SOMATROPIN RECOMBINANT;SAIZEN				I-440	AUG 26, 2007
>ADD>	019764 002	SOMATROPIN RECOMBINANT;SAIZEN				I-440	AUG 26, 2007
>ADD>	019764 003	SOMATROPIN RECOMBINANT;SAIZEN				I-440	AUG 26, 2007
	020080 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
			5037845	AUG 06, 2008	U72		
			4816470*PED	JUN 28, 2007			
			5037845*PED	FEB 06, 2009			
	020132 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
			5037845	AUG 06, 2008	U72		
			6368627	MAR 02, 2012	U444		
			5863559	JAN 26, 2016	U72		
			6020001	MAR 02, 2012	U444		
			6020001*PED	SEP 02, 2012			
			6368627*PED	SEP 02, 2012			
			4816470*PED	JUN 28, 2007			
			5037845*PED	FEB 06, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		5863559*PED	JUL 26, 2016			
020132 002	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 003	SUMATRIPTAN SUCCINATE;IMITREX	5037845	AUG 06, 2008	U72		
		4816470	DEC 28, 2006	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
020626 002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
020626 003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
021368 001	TADALAFIL;CIALIS	5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021368 002	TADALAFIL;CIALIS	5859006	JAN 12, 2016	DS DP		
			6140329	JUL 11, 2016	DP U155		
	021368 003	TADALAFIL;CIALIS	5859006	JAN 12, 2016	DS DP		
			6140329	JUL 11, 2016	DP U155		
	021388 001	TALC;TALC				ODE	DEC 24, 2004
	020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW	5045302	FEB 09, 2010			
	021200 001	TEGASEROD MALEATE;ZELNORM				I-435	AUG 21, 2007
	021200 002	TEGASEROD MALEATE;ZELNORM				I-435	AUG 21, 2007
	021144 001	TELITHROMYCIN;KETEK	D459798	SEP 24, 2015	DP	NCE	APR 01, 2009
			5635485	APR 21, 2015	DS DP U578		
	021124 002	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	5681849	OCT 28, 2014			
			4755534	DEC 30, 2006	U73		
			4680291	JUL 14, 2004	U73		
			6121314	MAY 18, 2012	U504		
	020846 001	TERBINAFINE;LAMISIL	5681849	OCT 28, 2014	DP		
			6121314	MAY 18, 2012	DP U504		
			6121314	MAY 18, 2012	DP U540		
			6121314	MAY 18, 2012	DP U502		
			6005001	MAY 18, 2012	DP U540		
			6005001	MAY 18, 2012	U502		
			6005001	MAY 18, 2012	U504		
			5856355	MAY 18, 2012	DP U502		
			5856355	MAY 18, 2012	U504		
			5856355	MAY 18, 2012	U540		
	021318 001	TERIPARATIDE RECOMBINANT HUMAN;FORTEO	6770623	DEC 08, 2018	DP U597		
	020785 001	THALIDOMIDE;THALOMID	6755784	SEP 23, 2020	U371		
	020785 002	THALIDOMIDE;THALOMID	6755784	SEP 23, 2020	U371		
	020785 003	THALIDOMIDE;THALOMID	6755784	SEP 23, 2020	U371		
	020898 001	THYROTROPIN ALFA;THYROGEN	6365127	NOV 24, 2015	DS DP U556		
>ADD>	021618 001	TINIDAZOLE;TINDAMAX				NCE	MAY 17, 2009
>ADD>						ODE	MAY 17, 2011
>ADD>						ODE	MAY 17, 2011
	021618 002	TINIDAZOLE;TINDAMAX				NCE	MAY 17, 2009
>ADD>						ODE	MAY 17, 2011
>ADD>						ODE	MAY 17, 2011
>ADD>	021682 001	TINIDAZOLE;TINDAMAX				ODE	MAY 17, 2011
>ADD>	021682 002	TINIDAZOLE;TINDAMAX				ODE	MAY 17, 2011
>ADD>	021395 001	TIOTROPIUM BROMIDE MONOHYDRATE;SPIRIVA	6777423	SEP 24, 2021	DS DP	NCE	JAN 30, 2009
			5610163	MAR 11, 2014	DS DP U566		
	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5658929	SEP 27, 2010			
	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5658929	SEP 27, 2010			
	021228 001	TOLTERODINE TARTRATE;DETROL LA	6770295	AUG 26, 2019	DP U544		
			6770295*PED	FEB 26, 2020			
	021228 002	TOLTERODINE TARTRATE;DETROL LA	6770295	AUG 26, 2019	DP U544		
			6770295*PED	FEB 26, 2020			
	020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			5998380	SEP 13, 2015	U598		
			6503884	OCT 13, 2015	U598		
	020505 002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			5998380	SEP 13, 2015	U598		
			6503884	OCT 13, 2015	U598		
	020505 003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			5998380	SEP 13, 2015	U598		
			6503884	OCT 13, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020505 004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			5998380	SEP 13, 2015	U598		
			6503884	OCT 13, 2015	U598		
	020505 005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			5998380	SEP 13, 2015	U598		
			6503884	OCT 13, 2015	U598		
	020505 006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			5998380	SEP 13, 2015	U598		
			6503884	OCT 13, 2015	U598		
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			6503884	OCT 13, 2015	U598		
			5998380	SEP 13, 2015	U598		
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			6503884	OCT 13, 2015	U598		
			5998380	SEP 13, 2015	U598		
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			6503884	OCT 13, 2015	U598		
			5998380	SEP 13, 2015	U598		
	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	DP		
			5849792	DEC 22, 2014	DP U383		
			5889052	DEC 02, 2014	DP U383		
			5510383	AUG 03, 2013	DP U383		
	021272 001	TREPROSTINIL SODIUM;REMODULIN	6765117	OCT 24, 2017	DS		
	021272 002	TREPROSTINIL SODIUM;REMODULIN	6765117	OCT 24, 2017	DS		
	021272 003	TREPROSTINIL SODIUM;REMODULIN	6765117	OCT 24, 2017	DS		
	021272 004	TREPROSTINIL SODIUM;REMODULIN	6765117	OCT 24, 2017	DS		
>ADD>	020404 003	TRETINOIN;AVITA				ODE	JUN 04, 2008
	021595 001	TROSPIUM CHLORIDE;SANCTURA				NCE	MAY 28, 2009
	020675 001	URSODIOL;URSO 250	4859660	NOV 19, 2007			
	021630 001	VORICONAZOLE;VFEND	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
			5364938	NOV 15, 2011	DS	I-409	NOV 14, 2006
			5567817	OCT 22, 2013	DS DP U540		
			5773443	JAN 25, 2011	DS DP U540		
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
			5312925	SEP 01, 2012	DS DP		
			6150366	MAY 27, 2019	DP		
			6245766	DEC 18, 2018	U601		
	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
			6150366	MAY 27, 2019	DP		
			6245766	DEC 18, 2018	U601		
			5312925	SEP 01, 2012	DS DP		
	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
			5312925	SEP 01, 2012	DS DP		
			6150366	MAY 27, 2019	DP		
			6245766	DEC 18, 2018	U601		
	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
			5312925	SEP 01, 2012	DS DP		
			6150366	MAY 27, 2019	DP		
			6245766	DEC 18, 2018	U601		
	021450 004	ZOLMITRIPTAN;ZOMIG	6750237	NOV 28, 2020	DP		
			6750237*PED	MAY 28, 2021			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as describled in 21 CFR 314.53(d)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
   DS = Drug Substance claim
   DP = Drug Product claim
   U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.